



Figure S1 Patients flow.

Table S1 Relapse-free survival evaluation in pathological variables

| Variable | Total number | Events | Percentage | P value |
|--------------------------------------|--------------|--------|------------|---------|
| Pathological response | | | | 0.574 |
| No | 34 | 8 | 76.5% | |
| Yes | 24 | 4 | 83.3% | |
| Overall | 58 | 12 | 79.3% | |
| HR | | | | 0.586 |
| Negative | 16 | 4 | 75.0% | |
| Positive | 42 | 8 | 81.0% | |
| Overall | 58 | 12 | 79.3% | |
| Pathological response in HR-positive | | | | 0.723 |
| No | 25 | 6 | 76.0% | |
| Yes | 17 | 2 | 88.2% | |
| Overall | 42 | 8 | 81.0% | |
| Pathological response in HR-negative | | | | 0.327 |
| No | 9 | 2 | 77.8% | |
| Yes | 7 | 2 | 71.4% | |
| Overall | 16 | 4 | 75.0% | |
| Ki 67 | | | | 0.897 |
| <20% | 8 | 2 | 75.0% | |
| ≥20% | 50 | 10 | 80.0% | |
| Overall | 58 | 12 | 79.3% | |

Table S1 (continued)

Table S1 (continued)

| Variable | Total number | Events | Percentage | P value |
|-------------------------|--------------|--------|------------|---------|
| p53 | | | | 0.566 |
| <10% | 25 | 6 | 76.0% | |
| ≥10% | 33 | 6 | 81.8% | |
| Overall | 58 | 12 | 79.3% | |
| Cancer stage | | | | 0.456 |
| IIA | 11 | 1 | 90.9% | |
| IIB + III | 47 | 11 | 76.6% | |
| Overall | 58 | 12 | 79.3% | |
| Inflammatory infiltrate | | | | 0.195 |
| No | 24 | 3 | 87.5% | |
| Yes | 34 | 9 | 73.5% | |
| Overall | 58 | 12 | 79.3% | |
| Angiolymphatic invasion | | | | 0.391 |
| No | 55 | 12 | 78.2% | |
| Yes | 3 | 0 | 100% | |
| Overall | 58 | 12 | 79.3% | |

HR, hormonal receptor.

Table S2 Overall survival evaluation in pathological variables

| Variable | Total number | Events | Percentage | P value |
|--------------------------------------|--------------|--------|------------|---------|
| Pathological response | | | | 0.085 |
| No | 34 | 7 | 79.4% | |
| Yes | 24 | 1 | 95.8% | |
| Overall | 58 | 8 | 86.2% | |
| HR | | | | 0.911 |
| Negative | 16 | 2 | 87.5% | |
| Positive | 42 | 6 | 85.7% | |
| Overall | 58 | 8 | 86.2% | |
| Pathological response in HR-positive | | | | 0.201 |
| No | 9 | 2 | 80.0% | |
| Yes | 7 | 2 | 94.1% | |
| Overall | 16 | 4 | 85.7% | |
| Pathological response in HR-negative | | | | 0.237 |
| No | 9 | 2 | 77.8% | |
| Yes | 7 | 0 | 100% | |
| Overall | 16 | 2 | 87.5% | |
| Ki 67 | | | | 0.813 |
| <20% | 8 | 1 | 87.5% | |
| ≥20% | 50 | 7 | 86.0% | |
| Overall | 58 | 8 | 79.3% | |
| p53 | | | | 0.229 |
| <10% | 25 | 5 | 80.0% | |
| ≥10% | 33 | 3 | 90.9% | |
| Overall | 58 | 8 | 86.2% | |
| Cancer Stage | | | | 0.192 |
| IIA | 11 | 0 | 100% | |
| IIB + III | 47 | 8 | 83.0% | |
| Overall | 58 | 8 | 86.2% | |
| Inflammatory infiltrate | | | | 0.306 |
| No | 24 | 2 | 82.4% | |
| Yes | 34 | 6 | 91.7% | |
| Overall | 58 | 8 | 86.2% | |
| Angiolymphatic invasion | | | | 0.391 |
| No | 55 | 8 | 85.5% | |
| Yes | 3 | 0 | 100% | |
| Overall | 58 | 8 | 86.2% | |

HR, hormonal receptor.